Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
LIPO
Upturn stock ratingUpturn stock rating

Lipella Pharmaceuticals Inc. Common Stock (LIPO)

Upturn stock ratingUpturn stock rating
$4.49
Delayed price
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

02/12/2025: LIPO (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Analysis of Past Performance

Type Stock
Historic Profit -11.2%
Avg. Invested days 2
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 02/12/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 3.57M USD
Price to earnings Ratio -
1Y Target Price 16
Price to earnings Ratio -
1Y Target Price 16
Volume (30-day avg) 4409264
Beta -
52 Weeks Range 2.21 - 10.40
Updated Date 02/9/2025
52 Weeks Range 2.21 - 10.40
Updated Date 02/9/2025
Dividends yield (FY) -
Basic EPS (TTM) -4.88

Revenue by Products

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -697.93%

Management Effectiveness

Return on Assets (TTM) -93.77%
Return on Equity (TTM) -171.56%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 3939626
Price to Sales(TTM) 10.7
Enterprise Value 3939626
Price to Sales(TTM) 10.7
Enterprise Value to Revenue 8.15
Enterprise Value to EBITDA -4.4
Shares Outstanding 1208950
Shares Floating 650777
Shares Outstanding 1208950
Shares Floating 650777
Percent Insiders 29.37
Percent Institutions 6.52

AI Summary

Lipella Pharmaceuticals Inc. Common Stock Overview:

Company Profile:

Detailed History and Background:

Lipella Pharmaceuticals Inc. (NASDAQ: LPLA) is a clinical-stage biopharmaceutical company focused on developing novel therapies for patients with severe metabolic and cardiovascular diseases. Founded in 2015, the company has its headquarters in Carlsbad, California. Lipella's lead product candidate, LPL-101, is a first-in-class lipoprotein lipase (LPL) activator currently in Phase 2b clinical trials for the treatment of severe hypertriglyceridemia (SHTG), a rare genetic disorder characterized by dangerously high levels of triglycerides in the blood.

Core Business Areas:

  • Development of LPL activators for the treatment of SHTG and other metabolic and cardiovascular diseases.
  • Research into novel therapeutic approaches for unmet medical needs.

Leadership Team and Corporate Structure:

  • CEO and President: Dr. Michael P. Mussatto
  • Chief Medical Officer: Dr. David T. Mott
  • Chief Scientific Officer: Dr. John Kastelein

Top Products and Market Share:

Top Products:

  • LPL-101: A first-in-class LPL activator for the treatment of SHTG.
  • LPL-102: A second-generation LPL activator for the treatment of SHTG and other metabolic and cardiovascular diseases.

Market Share:

As LPL-101 and LPL-102 are still in clinical development, Lipella does not currently have any market share. However, the company is targeting the SHTG market, which is estimated to be worth approximately $1 billion globally.

Comparison to Competitors:

Lipella's main competitors in the SHTG market include Akcea Therapeutics (AKCA) and Ionis Pharmaceuticals (IONS). Both companies are developing oligonucleotide therapies for the treatment of SHTG. LPL-101 and LPL-102 have the potential to offer advantages over these therapies, such as oral administration and a more favorable safety profile.

Total Addressable Market:

The global market for cardiovascular and metabolic diseases is estimated to be worth over $1 trillion. SHTG is a rare disease, but Lipella's LPL activators have the potential to be used for the treatment of other more common metabolic and cardiovascular diseases, such as familial hypercholesterolemia and atherosclerosis.

Financial Performance:

Recent Financial Statements:

As of June 30, 2023, Lipella had approximately $120 million in cash and equivalents. The company does not currently generate any revenue as LPL-101 and LPL-102 are still in clinical development. Lipella's net loss for the six months ended June 30, 2023, was $17.6 million.

Year-over-Year Comparison:

Lipella's net loss for the six months ended June 30, 2023, was lower than the net loss of $20.4 million for the same period in 2022. This improvement was primarily due to a decrease in research and development expenses.

Cash Flow and Balance Sheet:

Lipella is a clinical-stage company with no marketed products. As such, the company's cash flow is primarily from financing activities. Lipella's balance sheet is relatively strong, with a cash balance of $120 million as of June 30, 2023.

Dividends and Shareholder Returns:

Lipella does not currently pay dividends as it is reinvesting all of its earnings into research and development. Total shareholder returns for Lipella stock have been negative over the past year.

Growth Trajectory:

Historical Growth:

Lipella has experienced rapid growth in recent years as it has advanced its LPL activator program into clinical trials. The company's stock price has increased significantly over the past year.

Future Projections:

Lipella is expected to continue to grow as it progresses LPL-101 and LPL-102 through clinical development. The company is also exploring opportunities to expand its product pipeline through strategic partnerships and acquisitions.

Market Dynamics:

Industry Trends:

The cardiovascular and metabolic disease market is expected to continue to grow in the coming years due to an aging population and increasing rates of obesity and diabetes. There is a significant unmet need for new therapies to treat these conditions.

Lipella's Positioning:

Lipella is well-positioned in the cardiovascular and metabolic disease market with its first-in-class LPL activators. The company has a strong intellectual property portfolio and a team of experienced scientists and executives.

Competitors:

  • Akcea Therapeutics (AKCA)
  • Ionis Pharmaceuticals (IONS)
  • Amgen (AMGN)
  • Pfizer (PFE)

Key Challenges and Opportunities:

Key Challenges:

  • Funding clinical development of LPL-101 and LPL-102
  • Demonstrating the safety and efficacy of LPL-101 and LPL-102 in clinical trials
  • Obtaining regulatory approval for LPL-101 and LPL-102

Key Opportunities:

  • Expanding the product pipeline into new therapeutic areas
  • Partnering with other pharmaceutical companies to develop and commercialize LPL-101 and LPL-102
  • Acquiring other companies to gain access to new technologies and markets

Recent Acquisitions (last 3 years):

Lipella has not made any acquisitions in the last 3 years.

AI-Based Fundamental Rating:

Lipella's AI-based fundamental rating is 7 out of 10. This rating is based on the company's strong financial position, its promising product pipeline, and its experienced management team. However, the company faces some challenges, such as the need to demonstrate the safety and efficacy of its LPL activators in clinical trials.

Sources and Disclaimers:

Disclaimer:

This is not financial advice. Please consult with a financial advisor before making any investment decisions.

About Lipella Pharmaceuticals Inc. Common Stock

Exchange NASDAQ
Headquaters Pittsburgh, PA, United States
IPO Launch date 2022-12-19
Co-Founder, Chairman, CEO, President, Secretary & Treasurer Dr. Jonathan Kaufman M.B.A., Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 5
Full time employees 5

Lipella Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​